Literature DB >> 8322245

Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.

S Rodenhuis1, L G van't Hek, L T Vlasveld, R Kröger, R Dubbelman, R G van Tol.   

Abstract

OBJECTIVE: Major thromboses can occur in the venous system in association with central venous catheters. This usually necessitates removal of the catheter.
METHODS: The effectiveness of low dose recombinant tissue type plasminogen activator (rt-PA) in combination with heparin was assessed in patients with central venous catheter associated thrombosis.
RESULTS: In five patients, all suffering from cancer, a 5-7 day continuous infusion resulted in complete lysis of the thrombus without complications in three. In the other two patients moderately severe haemorrhage was observed with only partial lysis, of the thrombus.
CONCLUSIONS: The infusion of heparin and rt-PA is potentially effective in thrombosis related to use of central venous catheters, but the risk of haemorrhage is not inconsiderable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322245      PMCID: PMC464517          DOI: 10.1136/thx.48.5.558

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

Review 1.  Plasminogen activators. The old and the new.

Authors:  M S Runge; T Quertermous; E Haber
Journal:  Circulation       Date:  1989-02       Impact factor: 29.690

2.  Rapid resolution of subclavian vein thrombosis by tissue plasminogen activator.

Authors:  A Stewart; E E Mayne
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

3.  Venous thrombosis as a cause of superior vena cava syndrome. Rapid response to streptokinase.

Authors:  P O Katz; B T Hackshaw; C F Barish; B L Powell
Journal:  Arch Intern Med       Date:  1983-05

4.  Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.

Authors:  S Greenberg; R Kosinski; J Daniels
Journal:  Chest       Date:  1991-05       Impact factor: 9.410

5.  Iatrogenic superior vena cava syndrome. A new entity.

Authors:  M Bertrand; C A Presant; L Klein; E Scott
Journal:  Cancer       Date:  1984-07-15       Impact factor: 6.860

Review 6.  Superior vena cava obstruction syndrome: recommendations for management.

Authors:  J P Sculier; R Feld
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

7.  Safety and efficacy of thrombolytic therapy for superior vena cava syndrome.

Authors:  B H Gray; J W Olin; R A Graor; J R Young; J R Bartholomew; W F Ruschhaupt
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

  7 in total
  5 in total

Review 1.  Pulmonary embolism in parenteral nutrition.

Authors:  C M Dollery
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

Review 2.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

3.  Application of Aspiration-Assisted Percutaneous Venous Removal of Right Atrial Thrombus in a Critically Ill Patient: A Case Study and Clinical Management Overview.

Authors:  Khan Alam; Gehan A Pendlebury; Peter Oro; James McAlister; Tahreem Hashmi; Hasnan M Ijaz; Ali Chaudhry; Kevin Ergle
Journal:  Cureus       Date:  2022-09-06

4.  Metastatic carcinoma of unknown primary presenting as jugular venous thrombosis.

Authors:  Prince Cheriyan Modayil; Sathyan Panthakalam; David C Howlett
Journal:  Case Rep Med       Date:  2010-01-04

5.  High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach.

Authors:  E van der Wall; W J Nooijen; J W Baars; M J Holtkamp; J H Schorangel; D J Richel; E J Rutgers; I C Slaper-Cortenbach; C E van der Schoot; S Rodenhuis
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.